Translating Molecule Complexity
We integrate development pathways by combining predictive biopharmaceutics, advanced formulation engineering, and data-driven decision systems into a unified development pathway—designed to reduce uncertainty and enable clinical execution
Focused on complex, poorly soluble, and high-risk molecular assets.
- Solve exposure-limiting barriers (solubility, stability, variability)
- Predict human pharmacokinetics and clinical exposure early
- Translate complex molecules into execution-ready development pathways
Most molecules fail not due to lack of efficacy—but due to poor translation into clinically viable exposure and manufacturable form.
We design integrated development strategies that align molecular properties, formulation design, and clinical objectives from the outset—eliminating fragmented decision-making.
What we do:
- Combine modelling, formulation, and regulatory strategy into a unified plan
- Align preclinical data with clinical exposure targets
- Define development pathways that minimise rework and delays
When it matters:
- Early-stage assets with unclear development direction
- Programmes with repeated formulation or PK failures
- Assets transitioning from discovery to development
Outcome
Reduced development iterations, improved exposure predictability, and faster progression to clinical readiness.
We engineer formulation systems to overcome solubility, stability, and exposure limitations—transforming challenging molecules into clinically viable candidates.
What we do:
- Lipid-based systems, nanoemulsions, and advanced delivery platforms
- Solid-state optimisation and bioavailability enhancement
- Formulation strategies tailored to PK and clinical endpoints
- Enabling differentiation for lifecycle management and complex generics
When it matters:
- Poorly soluble (BCS II/IV) molecules
- High variability or inconsistent exposure
- Molecules failing due to formulation limitations
Outcome
Improved bioavailability, reduced variability, and clinically viable exposure profiles for challenging molecules.
We use mechanistic PK modelling and simulation to predict human exposure, guide formulation decisions, and reduce uncertainty before clinical studies.
What we do:
- PBPK modelling and simulation
- Dose prediction and exposure optimisation
- Scenario testing for formulation strategies
- IVIVC development and validation
When it matters:
- Pre-IND / preclinical stage
- First-in-human planning
- Dose selection uncertainty
Outcome
Informed dose selection, reduced clinical uncertainty, and higher probability of first-in-human success.
We ensure seamless transition from development to manufacturing by aligning formulation, process, and regulatory requirements early.
What we do:
- Scale-up strategy design
- Process optimisation and robustness
- CMC documentation aligned with global standards
When it matters:
- Transition from lab to GMP manufacturing
- Preparing for clinical supply
- Reducing scale-up failures
Outcome
Robust, scalable processes with reduced risk of manufacturing failure and regulatory delays.
SynapTx™ is our proprietary intelligence layer that integrates scientific literature, historical development data, and predictive modelling to guide high-stakes development decisions.
Deployment:
Secure, on-premise or controlled environments ensuring full data confidentiality.
What we do:
- Aggregates scientific literature, patents, and historical outcomes
- Identifies risks, opportunities, and alternative strategies
- Supports evidence-driven formulation and clinical decisions
When it matters:
- Reduces reliance on trial-and-error development
- Enables faster, data-driven decision-making
- Enhances probability of clinical success
Outcome
Faster, evidence-driven decisions with reduced reliance on trial-and-error experimentation.
Molecular Engineering
Characterising and engineering APIs to define critical quality attributes (CQAs), polymorphism, and stability risks early—ensuring downstream manufacturability and robustness.
Explore
Predictive Biopharmaceutics
Using mechanistic modelling to predict human exposure, guide formulation design, and inform dose strategy before first-in-human studies.
Bridging preclinical data to human exposure through mechanistic modelling—reducing clinical uncertainty
Complex & Novel Formulations
Solving solubility and bioavailability limitations to translate challenging molecules into viable therapies.
Enabling delivery of molecules that would otherwise fail due to poor solubility or bioavailability.
Technology Transfer & Scale-Up
Engineering seamless transition from development to manufacturing with ICH-aligned execution.
Ensuring reproducibility, scalability, and GMP-compliant execution
Nanotechnology & Targeted Delivery
Engineering controlled-release and targeted delivery architectures to optimise pharmacokinetics and therapeutic index
Enabling site-specific delivery and controlled activation
SynapTx™ AI Engine
SynapTx™ functions as the decision engine—analysing scientific, clinical, and formulation data to guide development strategy.
Integrating data intelligence into every stage of development decision-making.
A structured pathway to clinical translation
01
Data Aggregation IAggregation of internal datasets and external scientific evidence
02
Predictive Modelling Simulation of pharmacokinetics, degradation kinetics, and formulation behaviour
03
Strategy Generation Defining development strategy aligned with clinical and regulatory objectives
04
Clinical Translation Delivering execution-ready development programmes for clinical progression
When to engage us
Early-stage uncertainty
Formulation failure
Preclinical to clinical transition
Scale-up challenges
What differentiates our approach
Integrated thinking
Not isolated services—but a connected development pathway
Prediction-led development
Decisions guided by modelling and data—not trial-and-error
Execution focus
Designed for clinical and manufacturing success—not theoretical optimisation
Designed for high-stakes development programmes
Our work focuses on complex, high-risk molecular assets where conventional approaches fail. We partner selectively to build robust, data-driven pathways to clinical success.
Ready to de-risk your development programme?
Whether you are addressing formulation challenges, reducing clinical uncertainty, or preparing for scale-up—we enable better decisions earlier